GSK plc American Depositary Shares (Each representing two)

Biotech stocks have had a rough go so far this year, falling 12% compared with a 13% gain for the S&P 500. Morningstar sees opportunities.

The stock market’s gain this year, 17% based on the S&P 500, has some investors thinking that equities are overvalued.

While surging interest rates have taken a bite out of earnings, some companies have broken through the headwinds.

Equities have jumped this year, with the S&P 500 climbing 19%. But buying opportunities may still exist.

Morningstar assigned all five wide moat (durable competitive advantage) ratings and sees them as undervalued.

No one has gotten poor buying stocks of undervalued companies with strong fundamentals.

Given equities' surge so far this year, you'll want to guard against buying overvalued stocks.

These are companies whose products consumers will keep buying in any economic climate, Morningstar says.

Technical analysts Helene Meisler and Bruce Kamich offer insight into seven popular stocks.

Morningstar's 10 "best stocks to buy now" are the most undervalued among its 128 "best companies to own."

Out of its Best to Own List of 128 stocks, Morningstar chose the 10 it considers most undervalued.

Foreign equity markets have lagged the U.S. in recent years, making the valuations of overseas stocks attractive.

Morningstar created a list of the 10 most undervalued recession-resistant stocks.

'Healthcare is a sector that generally holds steady no matter what is happening in the economy,' the research firm said.

As of Nov. 11, just 29% of Morningstar-covered stocks that reported Q3 earnings beat estimates by at least 10%.

The research firm came up with a list of the best companies to own based on ones to which Morningstar analysts assign a wide moat.

Morningstar has put together a list of the Top 10 dividend stocks that are widely held by its 'ultimate stock-pickers.'

It defines best stocks as those with significant competitive advantages, and it thinks those advantages are growing.

The stock market has rebounded from earlier declines lately, with the S&P 500 jumping 13% since June 16.

Here's how to play the pharmaceutical giant.

Let's address the question that keeps coming up and where we stand for the rest of September. Plus, why the Utilities are important here.

It's hard to throw big punches when you view the current market surge skeptically, but there are ways to land the occasional jab successfully.

Here's what the charts of the pharmaceutical giant reveal.

As climate change creates a more volatile world with extreme storms and shifts in temperatures, these companies could benefit.

Let's review three pharma companies based outside the U.S. that promise reasonable valuations and solid dividend yields.

The sheer number of charts tell us daily how the concentration of money is so heavily invested in large caps versus small caps.

Despite most in a poll saying they prefer bonds over stocks for the next year, current asset allocation shows a huge majority of assets to be invested in stocks.

The plot thickens as worries of a downturn grow. But have the indicators really turned? Let's thumb through the charts -- and check out Disney.

There is considerable value to be found among international names at the moment.

These recession-resilient names offer above-average dividend yields and decent growth prospects.

Here's a way to trade Vir Biotechnology.

One reason to think bonds can rally some more is that the 2-Year Note has refused to break down further for the last three days.

Dip buyers -- will you see them this season? Also, let's check the indicators, the intermediate-term overbought reading to come, expected volatility and ... the chart of GOOGL.

Here's what to expect in the weeks and months ahead.

Risk-oriented investors should consider stepping into emerging and international positions.

After a deal with GlaxoSmithKline, the small-cap antibiotic developer Spero Therapeutics should get a shot as an options play.

Let's look at three high-yield dividend stocks to diversify your portfolio.

In this market environment, there is nothing wrong with a 'rinse, wash and repeat' trade.

The distressed retail chain files for Chapter 11 bankruptcy, facing macroeconomic headwinds.

Dr. Alan Baratz sits down with TheStreet to explain why Nvidia's CEO is "dead wrong" about quantum computing's future.

Here’s what could be next for AMD and its AI ambitions.